Snowball logo
logo
MRK_logo

Merck & Co., Inc

$134.89+$1.97  (1.48%)
Estimate
P/E
107.9
EPS
1.25
Beta
0.211
Growth
Revenue, YoY
4.27%
Net income, YoY
-183.48%
FCF, YoY
149.74%
Forecast
P/E (FWD)
14
EPS (FWD)
9.635
Dividends
Dividend yield
2.52%
Annual payout
$3.40
Next ex. div date
September 15, 26
Payout
92.12%
Div.growth, 5y
5.43%
Dividend growth streak
15 y
Div.rating
About the company
Ticker
MRK
ISIN
US58933Y1055
Country
United States of America
Sector (GICS)
Healthcare
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Frequently asked questions

What sector does Merck & Co., Inc (MRK) operate in?

Merck & Co., Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.

What is Merck & Co., Inc (MRK) current stock price?

As of the latest data, Merck & Co., Inc stock price is $134.89, with a previous close of $132.92. Merck & Co., Inc gained $1.97 in the last trading session, representing a 1.48% increase.

What is Merck & Co., Inc (MRK) current market capitalization?

Merck & Co., Inc market cap is approximately 333.15 billion.

What is Merck & Co., Inc (MRK) Earnings Per Share (EPS)?

The trailing EPS is $1.25, and the forward EPS is $9.63.

What is Merck & Co., Inc (MRK) Price-to-Earnings (P/E) ratio?

Merck & Co., Inc current P/E ratio is 107.91, with a forward P/E of 14.

What is Merck & Co., Inc (MRK) EBITDA?

Merck & Co., Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.02 billion.

Does Merck & Co., Inc (MRK) pay dividends?

Yes. Merck & Co., Inc pays quarterly dividends with an annualized yield of 2.52% and an estimated annual payout of $3.40 per share.

When is the next ex-dividend date for Merck & Co., Inc (MRK)?

The next ex-dividend date is scheduled for September 15, 2026.

How did Merck & Co., Inc (MRK) perform in its most recent earnings report?

In the last report (June 30, 2026), Merck & Co., Inc posted an EPS surprise of 12.93% and a revenue surprise of 2.77%.

When is Merck & Co., Inc (MRK) next earnings report?

Merck & Co., Inc is expected to release its next earnings report on September 30, 2026.

What is Merck & Co., Inc (MRK) beta (volatility) score?

Merck & Co., Inc has a beta of 0.211, indicating lower volatility than the overall market.